Core Viewpoint - The company, Tianyao Pharmaceutical Co., Ltd., anticipates a significant decline in net profit for the first half of 2025, projecting a decrease of 62.19% to 68.38% compared to the same period last year [1][2]. Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of approximately 44.9 million to 53.7 million yuan for the first half of 2025, a decrease of 88.32 million to 97.12 million yuan year-on-year [1][2]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be around 112 million to 121 million yuan, reflecting a year-on-year decrease of 18.59 million to 19.59 million yuan [1][2]. Group 2: Previous Year Performance - For the same period last year, the net profit attributable to shareholders was 142.02 million yuan [2]. - The basic earnings per share for the previous year were reported at 0.130 yuan [2]. Group 3: Reasons for Profit Decline - The decline in profit is attributed to the impact of the tenth batch of centralized procurement, which led to a decrease in the unit price of selected products, thereby reducing revenue and gross profit [2]. - The raw material pharmaceutical business faced intensified market competition, resulting in decreased sales volume and unit prices for certain products, further impacting revenue and profit [2].

第九届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届董事会第十 八次会议于 2025 年 7 月 11 日以通讯表决的方式召开。本次会议的通 知已于 2025 年 7 月 2 日以电子邮件的方式送达公司各位董事、监事 和高管人员。会议应参加表决董事 9 人，实际表决董事 9 人。会议符 合《公司法》和《公司章程》的有关规定，决议如下： 1.审议通过关于聘任公司副总经理的议案 经总经理李书箱先生提名，公司薪酬与提名委员会审议通过，聘 任陈洪先生为公司副总经理。陈洪先生简历如下： 证券代码：600488 证券简称：津药药业 编号：2025-041 津药药业股份有限公司 陈洪，男，1970 年出生，南京医科大学医学学士，长江商学院 EMBA 硕士。历任广州白云山和记黄埔中药有限公司常务副总经理，国 药控股和记黄埔医药（上海）有限公司总经理兼法人代表，和黄健宝 保健品有限公司总经理，广州和黄汉优有机产品有限公司总经理，和 黄医药高级副总裁、执行副总裁、首 ...

[Key Highlights](index=1&type=section&id=Key%20Highlights) The company anticipates a significant decline of 62.19% to 68.38% in net profit attributable to shareholders for the 2025 semi-annual period, with non-recurring net profit expected to decrease by 13.32% to 19.77% - This performance forecast applies to situations where profitability is achieved, but net profit has decreased by over 50% compared to the same period last year[3](index=3&type=chunk) 2025 Semi-Annual Performance Forecast | Metric | 2025 Semi-Annual Forecast (10,000 CNY) | Year-on-Year Change (10,000 CNY) | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 4,490 - 5,370 | Decrease 8,832.02 - 9,712.02 | Decrease 62.19% - 68.38% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 11,200 - 12,100 | Decrease 1,859.05 - 2,759.05 | Decrease 13.32% - 19.77% | [Current Period Performance Forecast](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) This section details the performance forecast for January 1 to June 30, 2025, indicating a year-on-year decline in both net profit attributable to shareholders and non-recurring net profit, with the forecast being unaudited - The performance forecast period is from January 1, 2025, to June 30, 2025[4](index=4&type=chunk) 2025 Semi-Annual Performance Forecast | Metric | 2025 Semi-Annual Forecast (10,000 CNY) | Year-on-Year Change (10,000 CNY) | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 4,490 - 5,370 | Decrease 8,832.02 - 9,712.02 | Decrease 62.19% - 68.38% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 11,200 - 12,100 | Decrease 1,859.05 - 2,759.05 | Decrease 13.32% - 19.77% | - The performance forecast presented herein is unaudited[4](index=4&type=chunk) [Prior Period Performance](index=1&type=section&id=Item%202.%20Prior%20Period%20Performance) This section presents the net profit attributable to shareholders, non-recurring net profit, and basic earnings per share for the 2024 semi-annual period, serving as the comparative baseline for the current forecast 2024 Semi-Annual Actual Performance | Metric | 2024 Semi-Annual Actual (10,000 CNY) | | :--- | :--- | | Net Profit Attributable to Shareholders | 14,202.02 | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 13,959.05 | | Basic Earnings Per Share | 0.130 CNY | [Main Reasons for Performance Decline](index=2&type=section&id=Item%203.%20Main%20Reasons%20for%20Performance%20Decline) The anticipated performance decline is primarily due to multiple factors including centralized procurement, intensified international market competition, and administrative fines for monopolistic behavior, leading to a year-on-year decrease in sales revenue and profit - The company's sales revenue and profit experienced a certain degree of year-on-year decline this year, influenced by factors such as centralized procurement and intensified international market competition[7](index=7&type=chunk) - The pharmaceutical preparation business saw a year-on-year decrease in revenue and gross profit due to the impact of the tenth batch of centralized procurement, which led to a decline in the unit price of winning bid products[7](index=7&type=chunk) - The active pharmaceutical ingredient (API) business experienced a year-on-year decline in revenue and profit, as both sales volume and unit prices of some products decreased due to intensified market competition[7](index=7&type=chunk) - The company incurred an administrative fine of **69.1924 million CNY** this year due to monopolistic behavior[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=Item%204.%20Risk%20Warning) The company declares that there are no significant uncertainties affecting the accuracy of this performance forecast - There are no significant uncertainties affecting the accuracy of this performance forecast[8](index=8&type=chunk) [Other Explanatory Notes](index=2&type=section&id=Item%205.%20Other%20Explanatory%20Notes) Investors are reminded that the forecast data is preliminary, and final financial figures will be based on the officially disclosed semi-annual report, with a caution regarding investment risks - The aforementioned forecast data represents preliminary calculations by the company's finance department[9](index=9&type=chunk) - Should there be a significant discrepancy between the disclosed performance forecast and actual results, the company will promptly issue a revised performance forecast announcement[9](index=9&type=chunk) - The specific and accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to be aware of investment risks[9](index=9&type=chunk)

津药药业（600488）公告，预计2025年半年度实现归属于上市公司股东的净利润约为4490万元到5370万 元，与上年同期相比将减少8832.02万元到9712.02万元，同比减少62.19%到68.38%。公司预计2025年半 年度实现归属于上市公司股东的扣除非经常性损益的净利润约为1.12亿元到1.21亿元，与上年同期相比 将减少1859.05万元到2759.05万元，同比减少13.32%到19.77%。 ...

津药药业股份有限公司 津药药业股份有限公司 会议资料 津药药业股份有限公司 $$\langle\exists\exists\exists\exists\exists\forall\exists\exists\exists\exists\exists\exists$$ 津药药业 2025 年第二次临时股东大会会议议案之一 关于控股子公司以自有资产抵押申请贷款 暨关联交易的议案 (已经 2025 年 6 月 25 日第九届董事会第 17 次会议审议通过) 一、关联交易概述 （一）本次交易的基本情况 津药药业股份有限公司(以下简称"公司")于 2023 年 12 月 20 日经第九届董事会第三次会议、2024 年 1 月 10 日经 2024 年第一次 临时股东大会审议通过"关于公司与天津医药集团财务有限公司关联 交易的议案"，公司与天津医药集团财务有限公司（以下简称"财务 公司" ）签订《金融服务协议》，财务公司向公司提供金融服务总额不 超过 12.03 亿元（详见公司公告 2023-086#）。 公司于 2024 年 6 月 17 日经第九届董事会第八次会议与公司第九 届监事会第六次会议审议通过"关于控股子公司 ...

会议资料 2025 年 7 月 津药药业股份有限公司 2025 年第二次临时股东大会 津药药业股份有限公司 2025 年第二次临时股东大会 2 / 7 津药药业股份有限公司 2025 年第二次临时股东大会 津药药业 2025 年第二次临时股东大会会议议案之一 1 / 7 津药药业股份有限公司 2025 年第二次临时股东大会 目录 1.关于控股子公司以自有资产抵押申请贷款暨关联交易的议案 ............ 3 关于控股子公司以自有资产抵押申请贷款 暨关联交易的议案 (已经 2025 年 6 月 25 日第九届董事会第 17 次会议审议通过) 一、关联交易概述 （一）本次交易的基本情况 津药药业股份有限公司(以下简称"公司")于 2023 年 12 月 20 日经第九届董事会第三次会议、2024 年 1 月 10 日经 2024 年第一次 临时股东大会审议通过"关于公司与天津医药集团财务有限公司关联 交易的议案"，公司与天津医药集团财务有限公司（以下简称"财务 公司"）签订《金融服务协议》，财务公司向公司提供金融服务总额不 超过 12.03 亿元（详见公司公告 2023-086#）。 公司于 2024 年 ...

Core Viewpoint - The cosmetics industry in Shandong Province is entering a phase of high-quality development, but it faces unprecedented challenges. The industry must leverage technology and brand strength to reshape its landscape and achieve sustainable growth [2][9]. Group 1: Industry Development and Challenges - The 2025 Northern Beauty Valley Conference highlighted the need for deep integration of production, education, research, and application to promote high-quality development in the cosmetics industry [3][28]. - The industry is experiencing significant growth, with the output value increasing from 20 billion to 30 billion from 2022 to 2024, driven by the Northern Beauty Valley initiative [28]. Group 2: Technological Innovations - Technological innovation is identified as the core driving force for high-quality development in the cosmetics industry [6][9]. - Breakthroughs in synthetic biology, such as the development of royal jelly acid, are paving the way for innovative raw materials in cosmetics [11]. - The introduction of transdermal absorption technology has significantly improved the efficiency of active ingredients in cosmetics [15]. Group 3: Cultural and Brand Strategies - The integration of traditional Chinese medicine with modern molecular biology is providing innovative solutions for effective cosmetic development [17]. - Shandong beauty companies are adopting a "cultural empowerment + digital marketing" strategy to enhance brand competitiveness [21][24]. - The brand "Yilian" achieved a revenue of 250 million in the first quarter of 2025, reflecting a 25% year-on-year growth, driven by its dual strategy of technology and culture [24]. Group 4: Collaborative Efforts and Future Directions - The Northern Beauty Valley is fostering collaboration among government, enterprises, universities, and research institutions to create a resource-sharing ecosystem [28][29]. - The establishment of a high-end think tank with 80 expert members aims to support technological advancements in the cosmetics industry [28][29]. - The Shandong Cosmetics Association is compiling a directory of unique cosmetic raw materials to enhance innovation and support the industry's development [19].

证券代码：600488 证券简称：津药药业 编号：2025-040 及慢性肾功能衰竭患者。2024 年 6 月津药和平向国家药品监督管理局药品审评中心提交 低钙腹膜透析液一致性评价补充申请并获受理。截至目前，津药和平在低钙腹膜透析液项 目上已累计投入研发费用约 1,124 万元。 津药药业股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天津）制药有 限公司（以下简称"津药和平"）收到国家药品监督管理局核准签发的低钙腹膜透析液（以 下简称 "该药品"或"本品"）的《药品补充申请批准通知书》，批准本品通过仿制药 质量和疗效一致性评价（以下简称"一致性评价"）。现将相关情况公告如下： 二、其他相关情况 低钙腹膜透析液适用于因非透析治疗无效而需要连续不卧床性腹膜透析治疗的急性 1 / 2 药品名称 低钙腹膜透析液（乳酸盐-G1.5%） 低钙腹膜透析液（乳酸盐-G2.5%） 剂型 注射剂 注射剂 注册分类 化学药品 ...

津药药业（600488）公告，子公司津药和平(天津)制药有限公司收到国家药品监督管理局核准签发的低 钙腹膜透析液的《药品补充申请批准通知书》，批准本品通过仿制药质量和疗效一致性评价。低钙腹膜 透析液适用于因非透析治疗无效而需要连续不卧床性腹膜透析治疗的急性及慢性肾功能衰竭患者。 ...

Core Viewpoint - The company aims to enhance its compliance management system to ensure legal and regulatory adherence, mitigate compliance risks, and support sustainable development [1][2][4]. Compliance Management Framework - The compliance management system applies to the company and its subsidiaries, including wholly-owned, controlled, and actual controlled enterprises [1]. - The system emphasizes adherence to national laws, regulations, industry standards, and internal policies [1][2]. Key Areas of Focus - The company will prioritize compliance in critical areas such as anti-commercial bribery, anti-monopoly, and fair competition [2][4]. - There will be a strong emphasis on contract management, ensuring legality and procedural correctness [3][4]. Risk Management - A comprehensive management system will be established to prevent violations, with adjustments made to investment plans in response to significant changes in external environments or project conditions [2][4]. - The company will conduct regular compliance risk assessments and implement preventive measures [6][7]. Training and Awareness - Compliance training will be mandatory for management and key personnel to foster a culture of compliance [9]. - Employees will be required to sign compliance commitments to reinforce the importance of legal and ethical conduct [9][10]. Monitoring and Reporting - The compliance department will oversee the implementation of compliance requirements and conduct investigations into violations [6][11]. - Any significant compliance incidents must be reported to the relevant departments within two working days [7][11]. Accountability and Enforcement - The company will establish clear accountability standards for compliance breaches, with potential disciplinary actions for violations [10][11]. - Whistleblower protections will be in place to encourage reporting of compliance issues without fear of retaliation [10][11].